Published in Vaccine on June 02, 2003
FaaPred: a SVM-based prediction method for fungal adhesins and adhesin-like proteins. PLoS One (2010) 0.94
Toward a new vaccine for pertussis. Proc Natl Acad Sci U S A (2014) 0.83
Immunogenicity and reactogenicity of two diphtheria-tetanus-whole cell pertussis vaccines in Iranian pre-school children, a randomized controlled trial. Hum Vaccin Immunother (2013) 0.80
Pertussis-specific memory B-cell and humoral IgG responses in adolescents after a fifth consecutive dose of acellular pertussis vaccine. Clin Vaccine Immunol (2014) 0.76
Vaccination site reaction or bacterial cellulitis? Paediatr Child Health (2009) 0.76
Discolored leg syndrome after vaccination--descriptive epidemiology. Eur J Pediatr (2008) 0.75
Parental reports of adverse events following simultaneously given dT-IPV and MMR vaccines in healthy 9-year-old children. Eur J Pediatr (2010) 0.75
Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis (2005) 3.06
Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. J Pediatr (2003) 2.42
Conquering the crippler: Canada and the eradication of polio. Can J Public Health (2005) 2.04
A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine (2003) 1.60
Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA (2005) 1.51
Immune activation and depression in women with rheumatoid arthritis. J Rheumatol (2004) 1.34
Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine (2003) 1.29
Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine (2002) 1.29
Increasing incidence of hospitalization for bronchiolitis among Canadian children, 1980-2000. J Infect Dis (2003) 1.26
Invasive infections caused by haemophilus influenzae serotypes in twelve Canadian IMPACT centers, 1996-2001. Pediatr Infect Dis J (2007) 1.23
Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with streptococcus pneumoniae in children in Calgary, Canada. Pediatr Infect Dis J (2008) 1.18
Progress in the prevention of pneumococcal infection. CMAJ (2005) 1.14
Thrombocytopenia after immunization of Canadian children, 1992 to 2001. Pediatr Infect Dis J (2003) 1.12
The effect of funded varicella immunization programs on varicella-related hospitalizations in IMPACT centers, Canada, 2000-2008. Pediatr Infect Dis J (2012) 1.04
Microarray analysis of nitric oxide responsive transcripts in Arabidopsis. Plant Biotechnol J (2004) 1.03
Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics (2004) 1.02
Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study. Clin Invest Med (2002) 1.01
Techniques for labia minora reduction: an algorithmic approach. Aesthetic Plast Surg (2009) 1.00
A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogs. Hum Gene Ther (2011) 1.00
A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age. Vaccine (2009) 0.98
How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine? Pediatr Infect Dis J (2006) 0.98
Definitive neuroradiological diagnostic features of tuberculous meningitis in children. Pediatr Radiol (2004) 0.95
Lack of evidence of encephalopathy related to pertussis vaccine: active surveillance by IMPACT, Canada, 1993-2002. Pediatr Infect Dis J (2004) 0.95
An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus. Can J Infect Dis Med Microbiol (2006) 0.95
Cortisol, behavior, and heart rate reactivity to immunization pain at 4 months corrected age in infants born very preterm. Clin J Pain (2010) 0.94
Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine (2006) 0.94
Canadian Association for Immunization Research and Evaluation (CAIRE) guidelines for industry-sponsored clinical trial and epidemiology contract research. Hum Vaccin (2005) 0.93
The accuracy of outcome prediction models for childhood-onset epilepsy. Epilepsia (2005) 0.92
Nationwide canadian study of hepatitis a antibody prevalence among children eight to thirteen years old. Pediatr Infect Dis J (2005) 0.92
Comparison of retinal vasodilator and constrictor responses in type 2 diabetes. Acta Ophthalmol (2012) 0.89
Humoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogs. Hum Gene Ther (2012) 0.89
Evaluation of endogenous acidic metabolic products associated with carbohydrate metabolism in tumor cells. Cell Biol Toxicol (2009) 0.89
Safety and immunogenicity of a Proteosome -trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine (2005) 0.89
The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine. CMAJ (2011) 0.88
Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. Pediatrics (2003) 0.88
Impaired retinal vasodilator responses in prediabetes and type 2 diabetes. Acta Ophthalmol (2013) 0.86
Value of early follow-up CT in paediatric tuberculous meningitis. Pediatr Radiol (2005) 0.86
Ciclosporin use during pregnancy. Drug Saf (2013) 0.85
Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults. Hum Vaccin (2005) 0.85
Cognitive elements in clinical decision-making: toward a cognitive model for medical education and understanding clinical reasoning. Adv Health Sci Educ Theory Pract (2009) 0.84
High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults. HIV Clin Trials (2012) 0.83
Use of lidocaine-prilocaine patch to decrease intramuscular injection pain does not adversely affect the antibody response to diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate and hepatitis B vaccines in infants from birth to six months of age. Pediatr Infect Dis J (2002) 0.83
Group B streptococcal testing during pregnancy: survey of postpartum women and audit of current prenatal screening practices. J Obstet Gynaecol Can (2005) 0.82
Is pertussis immune globulin efficacious for the treatment of hospitalized infants with pertussis? No answer yet. Pediatr Infect Dis J (2007) 0.82
The precocious two-year-old: status of the lexicon and links to the grammar. J Child Lang (2005) 0.82
A pilot study to quantify parental anxiety associated with enrollment of an infant or toddler in a phase III vaccine trial. Vaccine (2003) 0.81
Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine. Hum Vaccin Immunother (2013) 0.81
Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of age. Can J Infect Dis Med Microbiol (2007) 0.81
Polio vaccine: the first 50 years and beyond. Biologicals (2006) 0.80
Safety and immunogenicity of 2 mixed primary infant immunization schedules of pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, and Haemophilus influenzae Type B vaccines at 2, 4, and 6 months of age: a randomized controlled trial. Pediatr Infect Dis J (2012) 0.79
Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age. Vaccine (2005) 0.79
High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine. J Clin Immunol (2014) 0.78
Do childhood vaccines cause thrombocytopenia? Paediatr Child Health (2009) 0.78
Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine (2011) 0.77
A randomized study to evaluate the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, haemophilus influenzae b, and meningococcal serogroup C combination vaccine administered to infants at 2, 4 and 12 months of age. Pediatr Infect Dis J (2014) 0.77
Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. Vaccine (2009) 0.77
Does vaccination with the varicella vaccine within four weeks after the measles, mumps and rubella vaccine reduce protection? Paediatr Child Health (2009) 0.76
Immunization delivery in British Columbia: perspectives of primary care physicians. Can Fam Physician (2014) 0.76
Vaccination site reaction or bacterial cellulitis? Paediatr Child Health (2009) 0.76
Improved efficacy of a licensed acellular pertussis vaccine, reformulated in an adjuvant emulsion of liposomes in oil, in a murine model. Clin Vaccine Immunol (2007) 0.75
How long can we expect pertussis protection to last after the adolescent booster dose of tetanus-diphtheria-pertussis (Tdap) vaccines? Paediatr Child Health (2007) 0.75
Questions and answers on immunization. Paediatr Child Health (2007) 0.75
Prenatal Screening for HIV in Nova Scotia: Survey of Postpartum Women and Audit of Current Prenatal Screening Practices. Can J Infect Dis Med Microbiol (2006) 0.75
Practical questions and answers about childhood immunization. Paediatr Child Health (2004) 0.75
Can children with minor illnesses be safely immunized? Paediatr Child Health (2011) 0.75
Conforming to ICMJE principles. CMAJ (2005) 0.75
Advances in lithography: introduction to the feature. J Opt Soc Am A Opt Image Sci Vis (2014) 0.75
Randomized, double-blind, placebo-controlled trial to assess the rate of recurrence of oculorespiratory syndrome following influenza vaccination among persons previously affected. Clin Infect Dis (2003) 0.75
Palliative care clinical trials: how nurses are contributing to integrated, evidence-based care. Int J Palliat Nurs (2011) 0.75
Postvaccination thrombocytopenia in Canada. Pediatr Infect Dis J (2010) 0.75
Capecitabine and sixth cranial nerve palsy. J Cancer Res Ther (2010) 0.75
A useful device for minor earlobe procedures. Plast Reconstr Surg (2008) 0.75
Erythema nodosum, Mycobacterium avium lymphadenitis, and a 15-mm Mantoux test. Pediatr Infect Dis J (2007) 0.75
Labia minora reduction: guidelines for procedure choice. Plast Reconstr Surg (2010) 0.75
Advances in lithography: introduction to the feature. Appl Opt (2014) 0.75
Challenges and opportunities for bacterial vaccine development in the 21(st) century. Curr Pharm Biotechnol (2013) 0.75
Regrettable lack of definition of the "well tolerated" vaccine. Vaccine (2010) 0.75